CORRECTIONS

Author Corrections

The May 20, 2008, abstract by Cloughesy et al, entitled, “A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)” [J Clin Oncol 26:15S, 2008 (suppl; abstr 2010b)], contained an error.

In Methods section, the dosage for BV in the first sentence was given as 10 mg/m², whereas it should have been 10 mg/kg as follows:

“From June 2006 to Feb 2007, 167 patients (pts) with recurrent GBM were randomized 1:1 to BV (**10 mg/kg** q 2 wks) (Arm 1,

n=85) or BV + CPT (340 mg/m² if enzyme-inducing anti-epileptic drugs (AEDs) and 125 mg/m² for non-AEDs) (Arm 2, n=82), stratified by KPS: 70-80, 90-100, and relapse (1st or 2nd). The co-primary endpoints were PFS6 (defined at 24-weeks) and objective response rate (ORR) determined by an independent radiology facility (IRF), with secondary endpoints of safety, PFS, and duration of response determined by IRF, and overall survival.”

The online version has been corrected in departure from the print. The authors apologize to the readers for the mistake.

DOI: 10.1200/JCO.2011.35.7681

The August 20, 2009, article by D’Amico et al, entitled, “Risk of Death From Prostate Cancer After Brachytherapy Alone or With Radiation, Androgen Suppression Therapy, or

Both in Men With High-Risk Disease” (J Clin Oncol 27:3923-3928, 2009), contained errors.

In Table 1, The following numbers and percentages were incorrectly given and should have been:

No. of High-Risk Factors	Brachytherapy (n = 221)		AST + Brachytherapy (n = 254)		EBRT + Brachytherapy (n = 217)		AST + EBRT + Brachytherapy (n = 650)	
	No.	%	No.	%	No.	%	No.	%
Any 1	210	95%	228	90%	198	91%	530	82%
Any 2	10	4.5%	21	8%	19	9%	106	16%
All 3	1	0.5%	5	2%	0	0%	14	2%

The number of high-risk factors was shown for descriptive purposes only and was not used in any of the analyses in the study; therefore, the study findings remain unchanged.

In Figure 1, the x-axis label was given in months, whereas it should have been in years, as follows: “Time Since Prostate Brachytherapy (Years).”

The authors apologize to the readers for the mistakes.

DOI: 10.1200/JCO.2011.35.7707

The October 20, 2010, article by Mascarenhas et al, entitled, “Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children’s Oncology Group” (J Clin Oncol 28:4658-4663, 2010), contained an error.

The Statistics & Data Center Grant received by James R. Anderson was indicated as Grant No. U10 CA9841, whereas it should have been Grant No. U10 CA98413.

The authors apologize to the readers for the mistake.

DOI: 10.1200/JCO.2011.35.7715